Last updated: Aug 20, 2026 · Built by a patient who got tired of scrolling ClinicalTrials.gov
Active interventional trials with status RECRUITING or NOT_YET_RECRUITING. A multi-phase trial (e.g. 1/2) is counted in each of its phases.
Biomarkers, stage, prior treatments — get a ranked shortlist in minutes.
Recruiting trials grouped by drug class. Trials with unclassifiable or non-therapeutic interventions are excluded from this view.
| NCT | Phase | Title | Mechanism |
|---|---|---|---|
| NCT06202183 | — | Exercise for Gut Microbiome in Patients With Young-Onset Colorectal Cancer Undergoing Chemotherapy: The COURAGE Trial | Unknown mechanism |
| NCT06995924 | — | Improving Uptake of Surveillance in Colorectal Cancer Survivors Through Navigation and Web Education | Unknown mechanism |
| NCT01174121 | 2 | Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer | Tumor infiltrating lymphocytes (TILs) plus PD-1 blockade -- adoptive cell therapy plus immune checkpoint inhibitor |
| NCT07446322 | 2 | FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal Cancer | VEGF -- monoclonal antibody (bevacizumab); DNA synthesis + topoisomerase I -- chemotherapy (FOLFIRI); Oncolytic virus (pelareorep) |
| NCT07636785 | 1, 2 | A Phase 1 and 2 Study of VMD-102 in Hepatocellular Carcinoma and Other Solid Tumors | Unknown mechanism |
| Sponsor | Recruiting trials |
|---|---|
| Fudan University | 68 |
| Sun Yat-sen University | 52 |
| Sixth Affiliated Hospital, Sun Yat-sen University | 25 |
| Second Affiliated Hospital, School of Medicine, Zhejiang University | 15 |
| M.D. Anderson Cancer Center | 15 |
Countries/regions with the most active trial sites for colorectal cancer. A multi-site trial is counted once per country/region.
Phase-1 trials whose listed start date falls within the last 12 months — the leading edge of the field.
| Start | NCT | Title | Mechanism |
|---|---|---|---|
| Nov 1, 2026 | NCT07587827 | Study Evaluating the Safety Feasibility and Efficacy of ODI-2001 Vaccine, a Personnalized Immunotherapy in Patients With Metastatic or Locally Advanced Colon Cancer or Pancreatic Cancer | Neoantigens + CTLA-4 -- personalized DNA neoantigen vaccine combined with immune checkpoint blockade (anti-CTLA4 antibody) |
| Nov 2026 | NCT07738939 | IKS04 Regimen in Advanced Solid Tumors That Express CA242 | CA242 -- antibody-drug conjugate (ADC) |
| Oct 30, 2026 | NCT07272642 | A Phase 1, Multicenter Imaging Study of LNTH-2403 in Participants With Locally Advanced or Metastatic Solid Tumors. | LRRC15 -- radiolabeled monoclonal antibody (radioimmunotherapy) |
| Sep 8, 2026 | NCT07416552 | A Study to Investigate CEA-PRIT 2.0 in Participants With Metastatic Colorectal Cancer (mCRC) | CEA -- pretargeted radioimmunotherapy (PRIT) |
| Sep 1, 2026 | NCT07277322 | Neoadjuvant Dupilumab and Toripalimab in MSS CRC Subjects With Resectable Liver Metastases | IL-4Rα -- monoclonal antibody (Dupilumab); PD-1 -- immune checkpoint inhibitor (Toripalimab) |
| Sep 2026 | NCT07545122 | A Phase 1a/1b, First-Time-in-Human Study of CT-202, a Nectin-4 Directed Bispecific Antibody, in Participants With Recurring Triple Negative Breast, Colorectal, Urothelial Cancers | Nectin-4 -- bispecific antibody (CT-202) |
| Aug 30, 2026 | NCT07750041 | A Phase Ib/II Study of SYS6090 Combination Therapy in Advanced Colorectal Cancer | VEGF -- monoclonal antibody (bevacizumab) combined with unknown mechanism of SYS6090 |
| Aug 29, 2026 | NCT07693751 | A Study to Assess Safety and Efficacy of SOT109 in Patients With Advanced Unresectable or Metastatic Colorectal Cancer | CDH17 -- targeted biological agent |
You've seen the colorectal cancer landscape. Now find the trials that fit your case.
Enter biomarkers, stage, and prior treatments — get ranked matches with eligibility breakdown in minutes.
Find My Matches →Source: ClinicalTrials.gov, synced daily. Aggregated by ClinTrialFinder.